TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9778551

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) combined with recombinant tissue plasminogen activator (rTPA) or streptokinase (STK)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (rTPA or STK alone)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO)
Number of subjects: 112
Study: 1927911

Group type: EXPERIMENTAL
Intervention: nisoldipine 10 mg once daily
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: nisoldipine 10 mg twice daily
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: nisoldipine 20 mg once daily
Number of subjects: 178

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 178
Study: 6752580

Group type: EXPERIMENTAL
Intervention: Single Indicator (SI) technique for estimating extravascular thermal volume (EVTV)
Number of subjects: 147
Study: 30649058

Group type: EXPERIMENTAL
Intervention: VACS Index 2.0 with albumin, white blood count, and BMI
Number of subjects: 28390

Group type: COMPARATOR
Intervention: VACS Index 1.0
Number of subjects: 28390
Study: 29251433

Group type: COMPARATOR
Intervention: Timely linkage-to-care and ART initiation (TLA)
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Prior familiarity with Community HIV-care Providers (CHiPs)
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Perception of clinics being overcrowded
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Inconvenient clinic opening hours
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Feelings of shame about having HIV
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Not feeling ready to seek treatment
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Preferring to wait until feeling sick
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Number of self-reported lifetime sexual partners
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Having HIV-positive partners on ART
Number of subjects: 705
Study: 23343932

Group type: EXPERIMENTAL
Intervention: Pentavalent bovine‐human reassortant rotavirus vaccine
Number of subjects: 558
Study: 22406729

Group type: EXPERIMENTAL
Intervention: Conventional composite resin with conventional etchant
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Glass ionomer resin adhesive
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Color-changing composite resin with conventional etchant
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Color-changing composite resin with self-etch primer
Number of subjects: 300
Study: 19101754

Group type: EXPERIMENTAL
Intervention: Daily oral 1 mg minodronate for 24 months
Number of subjects: 704

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 704
Study: 17336698

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 2314
Study: 15258682

Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg bid
Number of subjects: 28

Group type: COMPARATOR
Intervention: Ticlopidine 250 mg bid
Number of subjects: 28
Study: 11528141

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg twice a day, adjusted weekly until a minimum decrease of 20% in cardiac frequency achieved)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no beta-adrenergic blockade)
Number of subjects: 0
Study: 9401836

Group type: EXPERIMENTAL
Intervention: Ketamine (2.5, 3.5, or 6.0 mg/kg) via jet injector
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ketamine (dosage based on mg/m2 body surface area or mg/kg body weight)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 30
Study: 8438810

Group type: EXPERIMENTAL
Intervention: DT-aP vaccine
Number of subjects: 246

Group type: COMPARATOR
Intervention: WC-DTP vaccine
Number of subjects: 246
Study: 2979214

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg o.m. for 14 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29803836

Group type: EXPERIMENTAL
Intervention: Stent placement for a maximum of 2 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Balloon dilatation
Number of subjects: 65
Study: 26209256

Group type: EXPERIMENTAL
Intervention: Beta-carotene fortified synbiotic food
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control food
Number of subjects: 51
Study: 25491556

Group type: EXPERIMENTAL
Intervention: Open reduction and volar angle‐stable plate osteosynthesis (ORIF)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Closed reposition and casting
Number of subjects: 185
Study: 22717925

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (Cypher; Cordis, Miami Lakes, FL, USA; n=20 patients)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bare metal stents (Driver; Medtronic, Santa Clara, CA, USA; n=20 patients)
Number of subjects: 40
Study: 20130836

Group type: EXPERIMENTAL
Intervention: 5 mg morphine in 20 ml saline
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 20 ml 0.25% bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 20 ml saline (placebo)
Number of subjects: 60
Study: 18759644

Group type: EXPERIMENTAL
Intervention: Aripiprazole (APZ) at a mean dose of 6.7 mg/day
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Aripiprazole (APZ)
Number of subjects: 23
Study: 15981071

Group type: EXPERIMENTAL
Intervention: Suction drainage of the cavity
Number of subjects: 50

Group type: COMPARATOR
Intervention: No suction drainage of the cavity
Number of subjects: 50
Study: 12679354

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) 6 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: discontinuation of rhGH therapy
Number of subjects: 30
Study: 10482213

Group type: EXPERIMENTAL
Intervention: Autonomy supportive presentation style ("It's Your Choice")
Number of subjects: 400

Group type: COMPARATOR
Intervention: Non-autonomy supportive presentation style
Number of subjects: 400
Study: 8960947

Group type: EXPERIMENTAL
Intervention: Fish oils (12 capsules, 3.6 g/day of omega 3)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Soya oil (12 capsules per day)
Number of subjects: 40
Study: 2069440

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study: 6622502

Group type: EXPERIMENTAL
Intervention: 400 mg theophylline tablet taken as 2 halves
Number of subjects: 10

Group type: COMPARATOR
Intervention: 400 mg theophylline tablet taken whole
Number of subjects: 10
Study: 31831255

Group type: COMPARATOR
Intervention: CD40 blockade (Iscalimab)
Number of subjects: 0

Group type: COMPARATOR
Intervention: B-cell activating factor receptor (Ianalumab) inhibition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cathepsin-S (Petesicatib)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inducible costimulator of T cells ligand (prezalumab)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lymphotoxin beta receptor (baminercept)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other kinase inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transmembrane activator and calcium-modulator and cytophilin ligand interactor TACI fusion protein (RC18)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low dose recombinant interleukin-2 to expand T-regulatory cells
Number of subjects: 0
Study: 30870970

Group type: EXPERIMENTAL
Intervention: Watermelon (2 cups daily)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Isocaloric low-fat cookies
Number of subjects: 33
Study: 29119319

Group type: EXPERIMENTAL
Intervention: Olfactory stimulation with anise or cinnamon
Number of subjects: 50

Group type: COMPARATOR
Intervention: Odorless stimulation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Olfactory stimulation (only more mature newborns, n=39)
Number of subjects: 50
Study: 26720751

Group type: EXPERIMENTAL
Intervention: Osteoarthritis intervention group
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 300
Study: 25123917

Group type: EXPERIMENTAL
Intervention: SCP-neurofeedback
Number of subjects: 144

Group type: COMPARATOR
Intervention: EMG-biofeedback (active control)
Number of subjects: 144
Study: 21996047

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 150 mg/d
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 60 mg/d
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 19188529

Group type: EXPERIMENTAL
Intervention: 8-month course of nurse-delivered telephone-based collaborative care supervised by a psychiatrist and primary care expert
Number of subjects: 450

Group type: COMPARATOR
Intervention: usual care by their physicians
Number of subjects: 450
Study: 17874269

Group type: EXPERIMENTAL
Intervention: Intensive follow-up
Number of subjects: 2923

Group type: EXPERIMENTAL
Intervention: Regular surveillance with serum carcinoembryonic antigen
Number of subjects: 2923

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 2923

Group type: COMPARATOR
Intervention: Less intensive follow-up
Number of subjects: 2923
Study: 15005784

Group type: EXPERIMENTAL
Intervention: Use of episiotomy only for fetal indications (group a)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Use of episiotomy in addition at a tear presumed to be imminent (group b)
Number of subjects: 146
Study: 12174061

Group type: EXPERIMENTAL
Intervention: Graftskin therapy with aggressive debridement and standardized wound care
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standardized wound care alone with aggressive debridement
Number of subjects: 17
Study: 9714263

Group type: EXPERIMENTAL
Intervention: Venlafaxine, 37.5 mg twice daily (increased to 75 mg twice daily after 3 weeks if poor response)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Fluoxetine, 20 mg once daily (increased to 20 mg twice daily after 3 weeks if poor response)
Number of subjects: 382
Study: 7806723

Group type: EXPERIMENTAL
Intervention: 5 verbal process components
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 3 standard symptom intensity measures
Number of subjects: 39
Study: 2617209

Group type: EXPERIMENTAL
Intervention: 3 g of amoxycillin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1 g of amoxycillin combined with 1 g of probenecid
Number of subjects: 12
Study: 1150128

Group type: EXPERIMENTAL
Intervention: Cyproheptadine (Cypro)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Methysergide (Methyl)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cypro and Methy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Cypro, Methy, and Placebo
Number of subjects: 23

Group type: COMPARATOR
Intervention: Cypro (normal and acromegalic subjects) and Methy (normal subjects)
Number of subjects: 23
Study: 30914493

Group type: EXPERIMENTAL
Intervention: Positive pressure extubation
Number of subjects: 240

Group type: COMPARATOR
Intervention: Traditional extubation
Number of subjects: 240
Study: 28670249

Group type: EXPERIMENTAL
Intervention: Training program based on the Precede model, conducted during four sessions twice a week for one hour.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Training program based on the Precede model
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 120
Study: 25499162

Group type: EXPERIMENTAL
Intervention: External trigeminal nerve stimulation (eTNS)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control settings (crossover to effective device parameters)
Number of subjects: 35
Study: 23230072

Group type: EXPERIMENTAL
Intervention: VascuLuminator
Number of subjects: 770

Group type: COMPARATOR
Intervention: Control group (no VascuLuminator)
Number of subjects: 770
Study: 21768737

Group type: EXPERIMENTAL
Intervention: Soy protein (SP) formula containing 12 g of SP, given for 20 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Milk protein (MP) formula, given for 20 weeks
Number of subjects: 48
Study: 19537839

Group type: EXPERIMENTAL
Intervention: Lubiprostone 8 microg twice daily for 3 months
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Lubiprostone 8 microg twice daily
Number of subjects: 193
Study: 16414215

Group type: EXPERIMENTAL
Intervention: 100 mg/day isoflavone supplement (n=15)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Identical placebo capsules (n=14)
Number of subjects: 29
Study: 13678386

Group type: EXPERIMENTAL
Intervention: Oolong tea
Number of subjects: 11

Group type: COMPARATOR
Intervention: Green tea
Number of subjects: 11

Group type: COMPARATOR
Intervention: Water
Number of subjects: 11
Study: 10630138

Group type: EXPERIMENTAL
Intervention: Community-level intervention including HIV risk reduction workshops and community HIV prevention events
Number of subjects: 690
Study: 8808491

Group type: EXPERIMENTAL
Intervention: 1000 mg ascorbate per day for 4 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 19
Study: 1393763

Group type: EXPERIMENTAL
Intervention: Azelastine, 0.28 mg to each nostril
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 31373271

Group type: COMPARATOR
Intervention: IV antibiotics
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: PO antibiotics
Number of subjects: 1054
Study: 28785857

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Age of patients (25 years or older)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Onset age (younger than 24 years)
Number of subjects: 35
Study: 26478187

Group type: COMPARATOR
Intervention: Low-GI breakfast not including fructose content (LGI)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-GI breakfast including fructose beverage (LGIF)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-GI breakfast (HGI)
Number of subjects: 10
Study: 24518163

Group type: EXPERIMENTAL
Intervention: Variable-flow nasal CPAP (nCPAP)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Bubble CPAP (bCPAP) at pressures of 5, 7, and 9 cmH2O
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Nasal bi-level positive airway pressure (nBiPAP) at pressures of 5, 7/5, and 9/5 cmH2O
Number of subjects: 29

Group type: COMPARATOR
Intervention: Unsupported breathing
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: nCPAP
Number of subjects: 29
Study: 21519882

Group type: EXPERIMENTAL
Intervention: Panoramic radiography
Number of subjects: 183474

Group type: COMPARATOR
Intervention: CBCT
Number of subjects: 183474
Study: 20488837

Group type: EXPERIMENTAL
Intervention: Sensitivity designs in randomized clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Varying randomization methods, duration of follow-up, and use of surrogate endpoints
Number of subjects: 0

Group type: COMPARATOR
Intervention: Identical protocols across centres
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Significant results found with varied designs
Number of subjects: 0
Study: 17279849

Group type: EXPERIMENTAL
Intervention: Acceptance of dependence by close relationship partner
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental partner assistance during individual laboratory task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prior assessments of dependency acceptance
Number of subjects: 0
Study: 15629215

Group type: EXPERIMENTAL
Intervention: Fragile X premutation males
Number of subjects: 0

Group type: COMPARATOR
Intervention: CGG repeat length
Number of subjects: 0
Study: 12131220

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine (one or two doses)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Polysaccharide vaccine (one dose)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Combination of pneumococcal conjugate and polysaccharide vaccines (one dose of each)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 9607049

Group type: EXPERIMENTAL
Intervention: DTaP and DT
Number of subjects: 0

Group type: COMPARATOR
Intervention: DTPwc
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Injection in the buttock
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simultaneous administration of OPV and/or HBV
Number of subjects: 0
Study: 7618425

Group type: EXPERIMENTAL
Intervention: i.v. ketorolac tromethamine 30 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 2151275

Group type: EXPERIMENTAL
Intervention: Zoladex plus flutamide (Zoladex 3.6 mg every 4 weeks, flutamide 250 mg t.i.d.)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Zoladex plus flutamide
Number of subjects: 262
Study: 638824

Group type: EXPERIMENTAL
Intervention: Alfathesin
Number of subjects: 54

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Alfathesin and Thiopentone
Number of subjects: 54
Study: 31908178

Group type: EXPERIMENTAL
Intervention: PAT removal (group A, n = 90)
Number of subjects: 181

Group type: COMPARATOR
Intervention: PAT retention (group B, n = 91)
Number of subjects: 181
Study: 30122130

Group type: EXPERIMENTAL
Intervention: Vectorcardiographic beat‐to‐beat variability parameters in patients with pAF during sinus rhythm
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Heart rate independent parameters in patients with pAF during sinus rhythm
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control group (no history of AF)
Number of subjects: 229
Study: 26360494

Group type: EXPERIMENTAL
Intervention: Girl's education
Number of subjects: 364

Group type: COMPARATOR
Intervention: Mother's education
Number of subjects: 364

Group type: COMPARATOR
Intervention: No-intervention
Number of subjects: 364
Study: 25434967

Group type: EXPERIMENTAL
Intervention: Single-hormone artificial pancreas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual-hormone artificial pancreas
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional insulin pump therapy
Number of subjects: 0
Study: 23340533

Group type: EXPERIMENTAL
Intervention: Quinidine (50 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 21292803

Group type: EXPERIMENTAL
Intervention: Exercise/movement optimization intervention (12-week home-based program of shoulder strengthening and stretching exercises)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Exercise/movement optimization intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Attention control group (1-hour educational video)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 80
Study: 19059635

Group type: EXPERIMENTAL
Intervention: Whole-body hyperthermia (WBH) in combination with carboplatin
Number of subjects: 47
Study: 16919060

Group type: EXPERIMENTAL
Intervention: Intensive advice to withdraw the overused medication (Group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Standard out‐patient detoxification programme (advice+prednisone+preventive treatment) (Group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Standard in‐patient withdrawal programme (Group C)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 120
Study: 15230949

Group type: EXPERIMENTAL
Intervention: rFVIIa 90 micrograms kg(‐1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: rFVIIa 180 micrograms kg(‐1)
Number of subjects: 12
Study: 11164700

Group type: EXPERIMENTAL
Intervention: Rufinamide (400-1600 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rufinamide
Number of subjects: 50
Study: 9245470

Group type: EXPERIMENTAL
Intervention: Holistic cue integration mechanism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intersection cuing mechanism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Independent cuing mechanism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compound cue model
Number of subjects: 0
Study: 8270721

Group type: EXPERIMENTAL
Intervention: High frequency flow interrupted ventilation (HFFIV)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV)
Number of subjects: 24
Study: 2826550

Group type: EXPERIMENTAL
Intervention: IV enalaprilat 1.25 mg q6h for 24 hours, increased to 5 mg q6h for nonresponding patients
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31363946

Group type: EXPERIMENTAL
Intervention: Second Step SEL program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 29562147

Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy with antibiotics
Number of subjects: 396

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 396
Study: 26522058

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus CT guided (125)I-seed implantation (CTII)
Number of subjects: 57

Group type: COMPARATOR
Intervention: FOLFIRI alone
Number of subjects: 57
Study: 25403867

Group type: EXPERIMENTAL
Intervention: Chia flour (35 g/day) for 12 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 22362420

Group type: EXPERIMENTAL
Intervention: Double pass PDL (11 J/cm², second pass 6 minutes after the first pass)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Single pass PDL (12 J/cm²)
Number of subjects: 17
Study: 19590523

Group type: EXPERIMENTAL
Intervention: Excimer laser trabeculotomy (ELT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 30
Study: 17623738

Group type: EXPERIMENTAL
Intervention: Multidisciplinary fatigue management programme (MFMP)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo intervention programme
Number of subjects: 51

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 51
Study: 15751370

Group type: EXPERIMENTAL
Intervention: Total joint replacement surgery (hip or knee)
Number of subjects: 100
Study: 11934185

Group type: EXPERIMENTAL
Intervention: 1 percent penciclovir cream
Number of subjects: 4573

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 4573
Study: 10860034

Group type: EXPERIMENTAL
Intervention: Tetracycline fiber therapy
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17
Study: 8649265

Group type: EXPERIMENTAL
Intervention: SPf66 vaccine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no vaccine)
Number of subjects: 100